Caelum Biosciences Overview
- Founded
- 2015
- Status
- Private
- Latest Deal Type
- Early Stage VC
- Latest Deal Amount
- $69.9M
- Investors
- 2
Caelum Biosciences General Information
Description
Operator of a clinical-stage biotechnology comapny intended to develop treatments for rare and life-threatening conditions. The company is engaged in development of antibodies that work to break up pre-existing amyloid in tissues and to help the body's immune system remove the deleterious material, enabling patients with a greater chance to be a safe, receive well-tolerated therapy that promotes amyloid resolution and improve organ responses.
Contact Information
Website
www.caelumbio.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
- Rutgers Ecocomplex
- 1200 Florence Road
- Bordentown, NJ 08505
- United States
Caelum Biosciences Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Early Stage VC | 30-Jan-2019 | $69.9M | 000.00 | Completed | Clinical Trials - Phase 3 |
Caelum Biosciences Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Operator of a clinical-stage biotechnology comapny intended to develop treatments for rare and life-threatening conditio
Biotechnology
Bordentown, NJ
000.00
0000000000 0
000.00
000 0000
nim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequ
0000000000000
Ann Arbor, MI
0
As of 0000
000.00
00000000000
000.00
000000 0
re eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui offic
0000000000000
Williamsville, NY
00
As of 0000
00.000
000000000 -
00.000
Add Comparison
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialCaelum Biosciences Competitors (33)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| ONL Therapeutics | Venture Capital-Backed | Ann Arbor, MI | 0 | 000.00 | 00000000000 | 000.00 |
| 000000 00000000 | Venture Capital-Backed | Williamsville, NY | 00 | 00.000 | 000000000 - | 00.000 |
| 0000 0000 00000000 | Formerly VC-backed | Cambridge, MA | 000 | 00000 | 00000000000 | 00000 |
| 0000000 0000000000 | Formerly VC-backed | La Jolla, CA | 00 | 00000 | 00000000 | 00000 |
| 0000000 0000000000 | Formerly PE-Backed | Cambridge, MA | 000 | 00000 | 000000000 |
Caelum Biosciences Executive Team (2)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Michael Spector | Chief Executive Officer, President & Board Member | ||
| Susan Sobolov Ph.D | Chief Operating Officer |
Caelum Biosciences Board Members (12)
| Name | Representing | Role | Since |
|---|---|---|---|
| Harlan Weisman MD | Self | Board Member | 000 0000 |
| Lindsay Rosenwald MD | Self | Board Member | 000 0000 |
| Martin Goldman | Caelum Biosciences | Board Member | 000 0000 |
| Martine Zimmerman | Caelum Biosciences | Board Member | 000 0000 |
| Michael Spector | Caelum Biosciences | Chief Executive Officer, President & Board Member | 000 0000 |
Caelum Biosciences Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Alexion | Corporation | Minority | 000 0000 | 000000 0 | |
| Columbia Technology Ventures | University | Minority | 000 0000 | 000000 0 |